Phaseline

Targets › CDK19

CDK19 (Cyclin-dependent kinase 19): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.

Component of the Mediator complex, a transcriptional coactivator required for regulated expression of nearly all RNA polymerase II-dependent genes. Acts as a molecular bridge between gene-specific regulatory proteins and the basal RNA polymerase II transcription machinery. (UniProt, Q9BWU1)

Open in Phaseline: the race on CDK19, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ryvu TherapeuticsRVU120
CDK8 and CDK19 inhibitor
CDK8, CDK19Phase 2Acute Myeloid LeukemiaAug 2027

Conditions

Acute Myeloid Leukemia (1)

Modalities

small molecule (1)

Companies

Ryvu Therapeutics (1)

Related targets

CDK8 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.